Cu Ventures, Inc.

7 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Aug 2034

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Mar 5 to 10, 2027 · next Mar 5
1 fee due Aug 25, 2027
The maintenance fee for Substituted (4'-Hydroxyphenyl)CYCLOAKLKANE Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform (US 10,570,077) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
1 fee due Sep 19, 2027
The maintenance fee for Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same (US 11,931,321) comes due Sep 19, 2027. Unpaid by Mar 20, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

Patent	Title	Status	Expires	Confidence
US 9,855,223	Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same In force Term ends Aug 21, 2034 · From the USPTO record	In force	Term ends Aug 21, 2034	From the USPTO record
US 10,406,119	Compositions comprising a dendrimer-resveratrol complex making and using the same In force Ends no later than Aug 21, 2034 · From the USPTO record	In force	Ends no later than Aug 21, 2034	From the USPTO record
US 11,110,068	Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same In force Ends no later than Aug 21, 2034 · From the USPTO record	In force	Ends no later than Aug 21, 2034	From the USPTO record
US 10,570,077	Substituted (4'-Hydroxyphenyl)CYCLOAKLKANE Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform In force Term ends May 23, 2035 · Medium confidence	In force	Term ends May 23, 2035	Medium confidence
US 11,931,321	Compositions comprising a dendrimer-resveratrol complex and methods for making and using the same In force Term ends May 30, 2035 · From the USPTO record	In force	Term ends May 30, 2035	From the USPTO record
US 10,927,398	Compositions for CYP450 Phenotyping Using Saliva Samples In force Term ends Feb 11, 2037 · High confidence	In force	Term ends Feb 11, 2037	High confidence
US 11,747,352	Eplerenone for Phenotyping of CYP3A5 Enzyme Activity in Saliva Samples In force Term ends Oct 13, 2038 · High confidence	In force	Term ends Oct 13, 2038	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending

List them